,id,ticker,title,category,content,date,provider,url,article_id
34715,256230,ATRC,4 Stocks To Watch  DVAX  NHTC  WOOF  YRCW,opinion,"It was another good day on Wall Street  a nice follow through day  and the markets closed pretty well on top of everything else  so we ll see if there s more upside  For now  let s go over some of the stocks we traded today and a couple new ones that came up 
Dynavax Technologies Corporation  NASDAQ DVAX  is a beautiful chart and really nicely moving after consolidating  It popped 82 cents to 29 65  or 2 8   on nearly a million shares on Wednesday  That s the best volume in five days  The beauty of this pattern is that after the base broke  and it ran up to resistance  it pulled back a couple times to test the 26 70 range  or thereabouts  and moved up to over 30 on Wednesday at 30 39  The target is 34 34 1 2 going forward 
Natural Health Trends Corp   NASDAQ NHTC  has been a star all year  going from under a dollar in the early part of this year  all the way up to the mid 40 s  Recently  it triple topped near 44 45  and came down hard  formed a break away gap  and reversed on Wednesday  up 9 66 to 34 39  or 39   on 1 9 million shares  That s the biggest volume on an up day since we ve been tracking this stock and a huge day for this stock  There s some resistance  so we ll have to watch to see if it will get up through the 36 range  If it does  the next target is 39 1 2  followed by  eventually  the mid 40 s if it gets a follow through 
VCA Inc   NASDAQ WOOF  had a big earnings report and blew through resistance on Wednesday  up 5 88 to 60 10  or 11   on 1 9 million shares  which is strong volume for this stock  It reached a new  all time high at 61 36  Look for it to move to 65 66 short term 
YRC Worldwide Inc   NASDAQ YRCW  had a huge move on Wednesday  up 1 98 to 15 06  or 15   on 2 million shares  With 5 3 days to cover  and a move up to resistance  I d be carefully watching to see if this stock follows through  It did back off through two moving averages and declining topsline on Wednesday  But keep an eye on it  Secondary resistance and target is 17 55  and then 19 90 
Other stocks on Harry s Charts of the Day included AtriCure  Inc   NASDAQ ATRC   Calix Inc   NYSE CALX   Amicus Therapeutics  Inc   NASDAQ FOLD   NuVasive  Inc   NASDAQ NUVA   the Rubicon Project  Inc   NYSE RUBI   Shake Shack Inc   NYSE SHAK   U S  Silica Holdings  Inc   NYSE SLCA   and Intrexon Corporation  NYSE XON  ",2015-07-30,Harry Boxer,"https://www.investing.com/analysis/dvax,-nhtc,-woof,-yrcw-259930",259930
34716,256231,ATRC,Perrigo Plunges On  1 9B Tax Bill From Irish Government,opinion,"Perrigo Company plc   NYSE PRGO   announced that the Irish Office of the Revenue Commissioners has issued a Notice of Amended Assessment for a tax liability of  1 9 billion   1 636 billion  related to Elan Pharma  the entity which Perrigo acquired in 2013 Shares of the company plunged almost 30  on Dec 21  following the news of such huge tax liability  Perrigo s shares are down 57 5  so far this year compared with the  s decline of 9 2  The company is planning to file an appeal with the Irish revenue department  Perrigo strongly disagrees with the assessment and stated that no payment is required until all proceedings are complete   The proceedings are expected to take a few years to complete The notice from the Irish government stated that Elan Pharma is liable to pay the said tax amount related to the sale of Tysabri intellectual property and related assets to Biogen   NASDAQ BIIB   in 2013  Elan was eligible to receive an upfront payment and future contingent payments from Biogen  which were recognized as trading income attracting a taxrate of 12 5  However  the Irish revenue department stated in the notice that the sale related to Tysabri should be considered as chargeable gains subject to ahigher tax rate of 33   This led to a massive tax bill for Perrigo Perrigo has asked the Irish revenue department for clarification and additional documents in support of the bill  However  the authority has communicated to Perrigo thatno further information will be provided related to this tax bill and the latter should file an appeal by Dec 28  2018 Perrigo Company plc Price
    Zacks Ranks   Stocks to ConsiderPerrigo is a Zacks Rank  5  Strong Sell  stock Some better ranked stocks from the pharma space are Haemonetics Corporation   NYSE HAE   and AtriCure  Inc    NASDAQ ATRC    each carrying a Zacks Rank  2  Buy   You can see  Haemonetics  earnings per share estimates have moved up from  2 28 to  2 33 for 2018 and from  2 96 to  3 04 for 2019 over the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with the average beat being 21 27  AtriCure s loss estimates have narrowed from 88 cents per share to 87 cents per share for 2018 and from 64 cents to 56 cents for 2019 over the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  with the average beat being 11 81  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2018-12-23,Zacks Investment Research,https://www.investing.com/analysis/perrigo-plunges-on-19b-tax-bill-from-irish-government-200370729,200370729
34717,256232,ATRC,Perrigo Stock Up As Appeal Date For Irish Tax Bill Nears,opinion,"Shares of Perrigo Company plc   NYSE PRGO   rallied 11 5  on Dec 26 as the deadline to appeal against the tax bill of  1 9 billion from Ireland government approaches  Investors  sentiment was positive and they expect Perrigo to remain committed to its statement about filing an appeal with the Irish revenue department Last week  Perrigo received a notice from the Irish government which held Elan Pharma  a subsidiary of Perrigo  liable to pay the said tax amount related to its sale of Tysabri intellectual property and related assets to Biogen   NASDAQ BIIB   in 2013  Elan was eligible to receive an upfront payment and future contingent payments from Biogen  which were recognized as trading income  attracting a tax rate of 12 5  However  the Irish revenue department stated in the notice that the sale related to Tysabri should be considered as chargeable gains subject to a higher tax rate of 33   This led to a massive tax bill for Perrigo The company s stock had plunged nearly 30  last week  following the announcement of the tax bill notice in a SEC filing Perrigo s shares are down 53 3  so far this year compared with the  s decline of 11 5  In its SEC filing  the company stated that it is on track to file an appeal and expects the proceedings to continue over a period of a few years before completion  Moreover  per the filing  no payment related to tax bill is required until all proceedings are complete Perrigo strongly disagreed with the assessment by the Irish revenue department  which neither provided a detailed clarification nor furnished additional documents in support of the bill Perrigo Company plc Price
    Zacks Ranks   Stocks to ConsiderPerrigo is a Zacks Rank  5  Strong Sell  stock Some better ranked stocks from the pharma space are Haemonetics Corporation   NYSE HAE   and AtriCure  Inc    NASDAQ ATRC    Both the stocks carry a Zacks Rank  2  Buy   You can see  Haemonetics  earnings per share estimates have moved up from  2 28 to  2 33 for 2018 and from  2 96 to  3 04 for 2019 over the past 60 days  The company delivered positive earnings surprise in three of the trailing four quarters with the average beat being 21 27  AtriCure s loss estimates have narrowed from 88 cents per share to 87 cents per share for 2018 and from 64 cents to 56 cents for 2019 over the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters with the average beat being 11 81  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-26,Zacks Investment Research,https://www.investing.com/analysis/perrigo-stock-up-as-appeal-date-for-irish-tax-bill-nears-200371220,200371220
34718,256233,ATRC,AtriCure Gains Expanded Labeling For Atriclip  Braces LAA Arm,opinion,Shares of AtriCure  Inc    NASDAQ ATRC   hopped 0 22  to close at  26 82 yesterday  subsequent to the company s receipt of the FDA s 510 k  clearance for additional C claims of its well acclaimed AtriClip left atrial appendage  LAA  management devices  This FDA approval validates the company s efforts in gaining ground in the field of coronary artery disease and other cardiovascular disorders The Labeling Claim and ProspectsThe additional indication covers change from occlusion of the LAA to exclusion and also addition of electrical isolation as a labeling claim  Here   exclusion  shuts off and or eliminates the appendage from the left atrium  Meanwhile   occlusion  plugs the opening to prevent flow into the LAA  Per AtriCure  the electrical isolation claim was granted after testing  which demonstrated that when the LAA is excluded using an AtriClip device  the appendage can no longer conduct electrical activity Given the fact that approximately 2 5 million adults in the United States suffer AF  with the market estimated to reach  14 68 billion by 2026 at a CAGR of 14 1  from 2018 onward  according to  and the number is only expected to shoot up further with the rise in aging population  we believe the aforementioned 510 k  clearance for additional labeling claims for the AtriClip device stands a good chance to enhance the company s profit margins  going ahead In this regard  the company noted that on a global scale  AtriClip devices are currently the most widely implanted left atrial appendage management devices and have been used in more than 190 000 procedures worldwide Over the last few years  the company has largely expanded its AtriClip devices  labeling to reflect the growing clinical use of the equipment  With AtriCure s plan to gain an additional labeling extension in the future  we presume its customer base to grow consistently Market PotentialPer Research and Markets  the global LAAC  LAA Closure  device market is projected to see a CAGR of 30 6  between 2018 and 2024  Further  the report states that increasing incidences of atrial fibrillation in aged population are likely to drive the global LAAC device market  Share Price MovementOver the past year  shares of AtriCure have underperformed its   The stock has declined 23 9  against the industry s 1 2  growth Zacks Rank   Key PicksCurrently  AtriCure carries a Zacks Rank  3  Hold   A few better ranked stocks from the broader medical space are GW Pharmaceuticals PLC   NASDAQ GWPH    EssilorLuxottica Societe anonyme   OTC ESLOY   and Haemonetics Corporation   NYSE HAE    You can see GW Pharmaceuticals  estimates third quarter earnings growth rate is estimated at 72 77   The stock sports a Zacks Rank  1 Zacks  2  Buy  Ranked EssilorLuxottica s long term earnings growth rate is predicted at 8 7  Haemonetics has a Zacks Rank  2 and a long term earnings growth rate projection of 13 5  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/atricure-gains-expanded-labeling-for-atriclip-braces-laa-arm-200459500,200459500
34725,256240,ATRC,AtriCure Enters Overbought Territory ,opinion,AtriCure  Inc    NASDAQ ATRC   has moved higher as of late  but there could definitely be trouble on the horizon for this company  That is because ATRC is now in overbought territory with an RSI value of 75 94 What is RSI  RSI stands for  Relative Strength Index  and it is a popular indicator used by technically focused investors  It compares the average of gains in days that closed up to the average of losses in days that closed down  readings above 70 suggest an asset is overbought  while an RSI below 30 suggests undervalued conditions are present Other FactorsYet ATRC s high RSI value isn t the only reason for investors to be concerned  as there has been some decidedly negative earnings estimate revisions AtriCure s stock as of late  This is especially true when investors dive into some of these revisions in order to get a better picture of ATRC s prospects for the near term Over the past one month  investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year  The consensus estimate for ATRC s has also been on a downward trend over the same time period too  as the estimates have fallen 1 1  over the last two months If this wasn t enough  AtriCure also has a Zacks Rank  4  Sell which puts it into unfortunate company among its peers  So  given all of these factors  investors may want to consider exiting this stock now before it falls back to Earth  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-09,Zacks Investment Research,https://www.investing.com/analysis/atricure-enters-overbought-territory-200497873,200497873
34775,256290,ATRC,Healthcare equipment names lead healthcare sector higher,news,Edwards Lifesciences  EW  9 5    Baxter International  BAX  3 8    and Integra Lifesciences  IART  4 3   are all putting in big moves following impressive Q1 results That s spreading to other sector names like  AtriCure   ATRC  3 1    Cerus  CERS  7 7    and Endologix  ELGX  2 2    and helping the Health Care SPDR  XLV  0 7   to a gain more than triple that of the S P 500 today Source  Jeremy Cooke at BloombergNow read  S P 500 Valuation Dashboard   Update,2017-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-equipment-names-lead-healthcare-sector-higher-477724,477724
34776,256291,ATRC,AtriCure beats by  0 13  beats on revenue,news,AtriCure   NASDAQ ATRC   Q4 EPS of   0 08 beats by  0 13 Revenue of  46 1M   12 0  Y Y  beats by  0 74M Press ReleaseNow read ,2018-02-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/atricure-beats-by-013-beats-on-revenue-1312727,1312727
